Peking University Shenzhen Hospital, Peking University, Shenzhen, Guangdong Province, China.
Department of Public Health and Preventive Medicine, Changzhi Medical College, Changzhi, Shanxi, China.
Hum Vaccin Immunother. 2023 Aug 1;19(2):2222648. doi: 10.1080/21645515.2023.2222648. Epub 2023 Jun 14.
COVID-19 vaccination is effective for cancer patients without safety concerns. However, COVID-19 vaccination hesitancy is common among cancer patients. This study investigated factors affecting primary COVID-19 vaccination series completion rate among cancer patients in China. A multicentre cross-sectional study was conducted in four Chinese cities in different geographic regions between May and June 2022. A total of 893 cancer inpatients provided written informed consent and completed the study. Logistic regression models were fitted. Among the participants, 58.8% completed the primary COVID-19 vaccination series. After adjusting for background characteristics, concerns about interactions between COVID-19 vaccination and cancers/cancer treatment (adjusted odds ratios [AOR]: 0.97, 95%CI: 0.94, 0.99) were associated with lower completion of primary vaccination series. In addition, perceived higher risk of COVID-19 infection comparing to people without cancers (AOR: 0.46, 95%CI: 0.24, 0.88), perceived a high chance of having severe consequences of COVID-19 infection (AOR: 0.68, 95%CI: 0.51, 0.91) were also associated with lower completion rate. Being suggested by significant others (AOR: 1.32, 95%CI: 1.23, 1.41) and perceived higher self-efficacy to receive COVID-19 vaccination (AOR: 1.48, 95%CI: 1.31, 1.67) were positively associated with the dependent variable. Completion rate of primary COVID-19 vaccination series was low among Chinese cancer patients. Given the large population size and their vulnerability, this group urgently needs to increase COVID-19 vaccination coverage. Removing concerns about interactions between COVID-19 vaccination and cancers, using fear appeal approach, involving significant others, and facilitating patients to make a plan to receive COVID-19 vaccination might be useful strategies.
COVID-19 疫苗接种对癌症患者有效且无安全隐患。然而,癌症患者对 COVID-19 疫苗接种犹豫不决的情况较为普遍。本研究旨在调查影响中国癌症患者完成初级 COVID-19 疫苗接种系列的因素。本研究于 2022 年 5 月至 6 月在四个地理位置不同的中国城市进行了一项多中心横断面研究。共有 893 名癌症住院患者提供了书面知情同意书并完成了研究。采用逻辑回归模型进行分析。在参与者中,58.8%完成了初级 COVID-19 疫苗接种系列。在调整背景特征后,对 COVID-19 疫苗接种与癌症/癌症治疗之间相互作用的担忧(调整后的比值比 [AOR]:0.97,95%置信区间:0.94,0.99)与较低的初级疫苗接种系列完成率相关。此外,与无癌症的人相比,认为 COVID-19 感染风险更高(AOR:0.46,95%置信区间:0.24,0.88)、认为 COVID-19 感染严重后果的可能性较高(AOR:0.68,95%置信区间:0.51,0.91)也与较低的完成率相关。他人的建议(AOR:1.32,95%置信区间:1.23,1.41)和对 COVID-19 疫苗接种的自我效能感较高(AOR:1.48,95%置信区间:1.31,1.67)与因变量呈正相关。中国癌症患者完成初级 COVID-19 疫苗接种系列的比例较低。鉴于其庞大的人口规模和脆弱性,该群体迫切需要提高 COVID-19 疫苗接种率。消除对 COVID-19 疫苗接种与癌症相互作用的担忧、使用恐惧诉求方法、让他人参与并促进患者制定 COVID-19 疫苗接种计划可能是有用的策略。